



Akouos to Participate in Upcoming March Virtual Investor Conferences

March 24, 2022

BOSTON, March 24, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. ("Akouos") (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that Manny Simons, Ph.D., M.B.A., co-founder, president, and chief executive officer will participate in two upcoming virtual investor conferences in March:

- **H.C. Wainwright Gene Therapy and Gene Editing Conference**
 - Pre-recorded presentation available for on-demand viewing on Wednesday, March 30 at 7:00 a.m. EST.
 - Panel discussion titled "Unlocking the path to hearing restoration with gene therapy" on Wednesday, March 30 at 1:00 p.m. EST.

- **Guggenheim Genomic Medicines & Rare Disease Day** on Thursday, March 31.

Webcasts of the H.C. Wainwright presentation and panel discussion will be accessible through the investors section of www.akouos.com. To access each webcast, please go to the Akouos website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. Archived replays will be available on Akouos's website for 30 days following each event.

About Akouos

Akouos is a precision genetic medicine company dedicated to developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for individuals living with disabling hearing loss worldwide. Leveraging its precision genetic medicine platform that incorporates a proprietary adeno-associated viral (AAV) vector library and a novel delivery approach, Akouos is focused on developing precision therapies for forms of sensorineural hearing loss. Headquartered in Boston, Akouos was founded in 2016 by leaders in the fields of neurotology, genetics, inner ear drug delivery, and AAV gene therapy.

Contacts

Media:

Katie Engleman, 1AB
katie@1abmedia.com

Investors:

Courtney Turiano, Stern Investor Relations
Courtney.Turiano@sternir.com